TDMS Study 05111-02 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
1,2,3-TRICHLOROPROPANE
NTP Experiment-Test: 05111-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/14/94
Route: GAVAGE Time: 08:34:20
Facility: TSI Mason Research
Chemical CAS #: 96-18-4
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05111-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 08:34:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 6 MG/KG 20 MG/KG 60 MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 9 6
Early Deaths
Moribund 8 34 37 48
Dead 1 3 4 1
Accident 1
Survivors
Terminal Sacrifice 41 13
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (59) (56) (57) (59)
Sarcoma, Metastatic, Uterus 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 5 (9%) 7 (12%) 1 (2%)
Intestine Large (59) (60) (59) (60)
Anorectal Junction, Squamous Cell Carcinoma 1 (2%) 1 (2%)
Intestine Large, Cecum (59) (58) (56) (60)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Intestine Small, Duodenum (59) (56) (57) (60)
Intestine Small, Ileum (59) (59) (59) (60)
Intestine Small, Jejunum (59) (57) (58) (60)
Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Liver (60) (60) (60) (60)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 1 (2%) 3 (5%) 2 (3%)
Hepatocellular Adenoma 5 (8%) 7 (12%) 4 (7%) 10 (17%)
Hepatocellular Adenoma, Multiple 2 (3%) 2 (3%) 5 (8%) 26 (43%)
Histiocytic Sarcoma 2 (3%) 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Sarcoma, Metastatic, Uterus 1 (2%)
Squamous Cell Carcinoma, Metastatic 1 (2%) 2 (3%)
Squamous Cell Carcinoma, Metastatic, Stomach 24 (40%) 25 (42%) 14 (23%)
Mesentery (3) (17) (20) (10)
Sarcoma, Metastatic, Skin 1 (33%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (10%)
Sarcoma, Metastatic, Uterus 1 (10%)
Squamous Cell Carcinoma, Metastatic, Stomach 16 (94%) 19 (95%) 7 (70%)
Pancreas (59) (60) (60) (60)
Sarcoma, Metastatic, Skin 1 (2%)
Sarcoma, Metastatic, Uterus 1 (2%)
Page 2
NTP Experiment-Test: 05111-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 08:34:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 6 MG/KG 20 MG/KG 60 MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Squamous Cell Carcinoma, Metastatic, Stomach 17 (28%) 22 (37%) 8 (13%)
Pharynx (1) (1) (5)
Squamous Cell Carcinoma 1 (100%) 1 (20%)
Palate, Squamous Cell Carcinoma 4 (80%)
Palate, Squamous Cell Papilloma 1 (100%)
Salivary Glands (59) (60) (58) (59)
Stomach (60) (60) (60) (60)
Squamous Cell Papilloma 1 (2%)
Stomach, Forestomach (60) (59) (60) (60)
Squamous Cell Carcinoma 30 (51%) 29 (48%) 26 (43%)
Squamous Cell Carcinoma, Multiple 17 (29%) 26 (43%) 25 (42%)
Squamous Cell Papilloma 13 (22%) 14 (23%) 13 (22%)
Squamous Cell Papilloma, Multiple 15 (25%) 13 (22%) 20 (33%)
Stomach, Glandular (59) (60) (59) (59)
Tongue (1) (3) (1)
Squamous Cell Papilloma 1 (33%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (60) (57) (58) (59)
Adenoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%) 1 (2%) 1 (2%)
Adrenal Gland, Medulla (59) (54) (56) (59)
Islets, Pancreatic (59) (60) (59) (60)
Pituitary Gland (58) (56) (54) (58)
Pars Distalis, Adenoma 4 (7%) 2 (4%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (59) (58) (58) (59)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (59) (59) (57) (58)
Adenoma 1 (2%)
Cystadenoma 1 (2%)
Hemangioma 1 (2%)
Page 3
NTP Experiment-Test: 05111-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 08:34:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 6 MG/KG 20 MG/KG 60 MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 9 (15%) 4 (7%) 3 (5%)
Teratoma Malignant 1 (2%)
Oviduct (57) (58) (59) (57)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Uterus (60) (60) (60) (59)
Adenoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Polyp Stromal 2 (3%) 2 (3%) 7 (12%)
Sarcoma 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 2 (3%) 2 (3%)
Endometrium, Adenocarcinoma 4 (7%) 3 (5%) 8 (14%)
Endometrium, Adenoma 1 (2%) 3 (5%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (59) (60) (60)
Lymph Node (60) (59) (60) (60)
Mediastinal, Squamous Cell Carcinoma,
Metastatic, Stomach 5 (8%) 8 (13%) 4 (7%)
Pancreatic, Squamous Cell Carcinoma,
Metastatic, Stomach 1 (2%) 1 (2%)
Renal, Squamous Cell Carcinoma, Metastatic,
Stomach 1 (2%)
Lymph Node, Mandibular (56) (57) (57) (57)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Lymph Node, Mesenteric (58) (55) (59) (58)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 7 (13%) 16 (27%) 3 (5%)
Spleen (59) (60) (60) (58)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Uterus 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 6 (10%) 6 (10%) 4 (7%)
Thymus (56) (55) (57) (57)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%) 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (54) (45) (59) (59)
Adenoacanthoma 1 (2%) 3 (5%)
Adenocarcinoma 2 (4%) 1 (2%)
Skin (60) (60) (60) (60)
Subcutaneous Tissue, Sarcoma 2 (3%)
Page 4
NTP Experiment-Test: 05111-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 08:34:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 6 MG/KG 20 MG/KG 60 MG/KG
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (2) (11) (15) (5)
Hemangioma 1 (7%)
Squamous Cell Carcinoma, Metastatic, Stomach 10 (91%) 15 (100%) 3 (60%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (59) (59) (60) (60)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Adenoacanthoma, Metastatic, Mammary Gland 1 (2%) 1 (2%)
Alveolar/Bronchiolar Adenoma 3 (5%) 3 (5%) 10 (17%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 3 (5%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic 2 (3%)
Squamous Cell Carcinoma, Metastatic, Stomach 6 (10%) 9 (15%) 3 (5%)
Squamous Cell Carcinoma, Metastatic,
Intestine Large 1 (2%)
Mediastinum, Squamous Cell Carcinoma,
Metastatic, Stomach 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (7) (8) (10)
Adenoma 3 (100%) 6 (86%) 5 (63%) 9 (90%)
Bilateral, Adenoma 2 (25%) 1 (10%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (59) (60) (60) (60)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Uterus 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%) 3 (5%)
Urinary Bladder (59) (58) (60) (57)
Page 5
NTP Experiment-Test: 05111-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 08:34:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 6 MG/KG 20 MG/KG 60 MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 2 (3%) 1 (2%)
Lymphoma Malignant Histiocytic 1 (2%) 2 (3%)
Lymphoma Malignant Lymphocytic 2 (3%) 2 (3%) 2 (3%)
Lymphoma Malignant Mixed 1 (2%) 1 (2%)
Lymphoma Malignant Undifferentiated Cell 11 (18%) 4 (7%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05111-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 08:34:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 6 MG/KG 20 MG/KG 60 MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 39 54 59 60
Total Primary Neoplasms 45 115 113 181
Total Animals with Benign Neoplasms 20 36 40 53
Total Benign Neoplasms 20 52 47 106
Total Animals with Malignant Neoplasms 23 48 55 58
Total Malignant Neoplasms 25 63 66 75
Total Animals with Metastatic Neoplasms 1 28 36 28
Total Metastatic Neoplasm 2 116 147 67
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05111-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 08:34:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 6 MG/KG 20 MG/KG 60 MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 9
Early Deaths
Dead 7 7 4 3
Moribund 3 26 40 44
Survivors
Terminal Sacrifice 42 18
Wrong Sex 1
Animals Examined Microscopically 60 59 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (55) (54) (57) (59)
Sarcoma, Metastatic, Stomach 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 2 (4%) 1 (2%)
Intestine Large, Cecum (59) (57) (59) (59)
Intestine Small, Duodenum (57) (56) (60) (57)
Intestine Small, Ileum (58) (59) (60) (59)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Lymphoid Tissue, Histiocytic Sarcoma 1 (2%) 1 (2%)
Intestine Small, Jejunum (57) (56) (60) (59)
Adenoma 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 2 (3%)
Liver (60) (59) (60) (60)
Hemangioma 1 (2%)
Hemangiosarcoma 3 (5%)
Hepatocellular Carcinoma 4 (7%) 8 (14%) 6 (10%) 3 (5%)
Hepatocellular Carcinoma, Multiple 3 (5%)
Hepatocellular Adenoma 10 (17%) 11 (19%) 13 (22%) 6 (10%)
Hepatocellular Adenoma, Multiple 2 (3%) 7 (12%) 8 (13%) 25 (42%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Sarcoma, Metastatic, Stomach 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 13 (22%) 31 (52%) 29 (48%)
Mesentery (4) (15) (17) (16)
Hemangiosarcoma, Metastatic, Liver 1 (25%)
Histiocytic Sarcoma 1 (6%)
Histiocytic Sarcoma, Metastatic, Liver 1 (25%)
Sarcoma, Metastatic, Skeletal Muscle 1 (6%)
Squamous Cell Carcinoma, Metastatic, Stomach 13 (87%) 14 (82%) 15 (94%)
Pancreas (60) (58) (59) (59)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Page 8
NTP Experiment-Test: 05111-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 08:34:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 6 MG/KG 20 MG/KG 60 MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Sarcoma, Metastatic, Stomach 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 12 (21%) 16 (27%) 11 (19%)
Salivary Glands (60) (59) (60) (60)
Stomach (60) (59) (60) (60)
Histiocytic Sarcoma 1 (2%)
Stomach, Forestomach (60) (59) (60) (60)
Sarcoma 1 (2%)
Squamous Cell Carcinoma 27 (46%) 19 (32%) 36 (60%)
Squamous Cell Carcinoma, Multiple 14 (24%) 35 (58%) 19 (32%)
Squamous Cell Papilloma 3 (5%) 17 (29%) 15 (25%) 24 (40%)
Squamous Cell Papilloma, Multiple 18 (31%) 10 (17%) 11 (18%)
Tongue (2) (1) (1) (3)
Squamous Cell Papilloma 2 (67%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (59) (60) (60)
Histiocytic Sarcoma 1 (2%)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (60) (59) (57) (58)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 2 (3%)
Thyroid Gland (57) (59) (60) (60)
Histiocytic Sarcoma 1 (2%)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (60) (59) (60) (60)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 6 (10%) 5 (8%) 2 (3%)
Prostate (59) (58) (60) (57)
Squamous Cell Carcinoma, Metastatic, Stomach 2 (3%) 2 (4%)
Page 9
NTP Experiment-Test: 05111-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 08:34:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 6 MG/KG 20 MG/KG 60 MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Seminal Vesicle (60) (59) (60) (60)
Squamous Cell Carcinoma, Metastatic, Stomach 6 (10%) 9 (15%) 1 (2%)
Testes (60) (59) (59) (60)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (59) (60) (60)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node (60) (59) (60) (60)
Axillary, Histiocytic Sarcoma 1 (2%)
Bronchial, Squamous Cell Carcinoma,
Metastatic, Stomach 1 (2%)
Iliac, Squamous Cell Carcinoma, Metastatic,
Stomach 1 (2%)
Mediastinal, Histiocytic Sarcoma 1 (2%) 1 (2%)
Mediastinal, Sarcoma, Metastatic, Stomach 1 (2%)
Mediastinal, Squamous Cell Carcinoma,
Metastatic, Stomach 8 (14%) 4 (7%) 3 (5%)
Pancreatic, Squamous Cell Carcinoma,
Metastatic, Stomach 1 (2%)
Lymph Node, Mandibular (56) (55) (57) (53)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Lymph Node, Mesenteric (56) (56) (58) (58)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 6 (11%) 12 (21%) 5 (9%)
Mediastinal, Squamous Cell Carcinoma,
Metastatic, Stomach 1 (2%)
Spleen (60) (59) (60) (60)
Hemangioma 1 (2%) 1 (2%)
Hemangiosarcoma 2 (3%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 3 (5%) 9 (15%) 5 (8%)
Thymus (54) (47) (53) (49)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 3 (6%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05111-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 08:34:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 6 MG/KG 20 MG/KG 60 MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (57) (60) (59)
Prepuce, Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (59) (60) (60)
Osteosarcoma 1 (2%)
Skeletal Muscle (1) (13) (14) (9)
Histiocytic Sarcoma 1 (7%)
Sarcoma 1 (7%)
Sarcoma, Metastatic, Stomach 1 (11%)
Squamous Cell Carcinoma, Metastatic, Stomach 12 (92%) 11 (79%) 7 (78%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (58) (60) (60)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (59) (60) (60)
Alveolar/Bronchiolar Adenoma 6 (10%) 10 (17%) 3 (5%) 6 (10%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 2 (3%) 3 (5%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 2 (3%)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (5%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Stomach 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 6 (10%) 12 (20%) 7 (12%)
Nose (60) (59) (60) (60)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (3) (11) (13)
Adenoma 1 (100%) 2 (67%) 10 (91%) 11 (85%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 05111-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 08:34:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 6 MG/KG 20 MG/KG 60 MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (59) (60) (60)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 2 (3%)
Urinary Bladder (59) (58) (59) (59)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(59) *(60) *(60)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Lymphoma Malignant Histiocytic 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%) 1 (2%)
Lymphoma Malignant Undifferentiated Cell 4 (7%) 3 (5%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05111-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 08:34:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 6 MG/KG 20 MG/KG 60 MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 30 57 59 60
Total Primary Neoplasms 45 129 126 149
Total Animals with Benign Neoplasms 20 49 46 50
Total Benign Neoplasms 27 70 61 89
Total Animals with Malignant Neoplasms 15 44 56 58
Total Malignant Neoplasms 18 59 65 60
Total Animals with Metastatic Neoplasms 2 23 38 37
Total Metastatic Neoplasm 9 99 130 102
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 77223-77223/77223
--multipart-boundary--